A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Purpose

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

Condition

  • Multiple Myeloma

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2) - Measurable multiple myeloma (MM) - Eastern Cooperative Oncology Group performance status of 0-1

Exclusion Criteria

  • Condition that confounds the ability to interpret data from the study - Known active or history of central nervous system (CNS) involvement of MM Note: Other protocol-defined inclusion/exclusion criteria apply

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm A: BMS-986393 + Alnuctamab
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
  • Drug: Alnuctamab
    Specified dose on specified days
    Other names:
    • BMS-986349
    • CC-93269
    • EM901
Experimental
Arm B: BMS-986393 + Mezigdomide
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
  • Drug: Mezigdomide
    Specified dose on specified days
    Other names:
    • BMS-986348
    • CC-92480
Experimental
Arm C: BMS-986393 + Iberdomide
  • Drug: BMS-986393
    Specified dose on specified days
    Other names:
    • CC-95266
  • Drug: Iberdomide
    Specified dose on specified days
    Other names:
    • BMS-986382
    • CC-220

Recruiting Locations

University of Alabama at Birmingham
Birmingham, Alabama 35294-3300
Contact:
Susan Bal, Site 0008
205-934-1908

More Details

Status
Recruiting
Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Study Contact

BMS Study Connect Contact Center www.BMSStudyConnect.com
855-907-3286
Clinical.Trials@bms.com